We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Research Progress of C-Myc in Chronic Myelogenous Leukemia --Review].
Zhongguo Shi Yan Xue Ye Xue za Zhi 2019 Februrary
As a potential target for cancer treatment, the C-Myc high expresses abnormally in a variety of solid tumors and hematological malignancies in humans. In hematologic malignancies, the increasing expression of C-Myc is associated with poor prognosis of patients diffuse large B-cell lymphoma. However, some studies have shown that high expression of C-Myc might be one of the mechanisms of disease progression and abrupt change, therefore, it can promote the transformation of chronic myeloid leukemia. Besides, the high expression of C-Myc may lead to the decrease of the sensitivity of chronic myelogenous leukemia cells to imatinib. Therefore, C-Myc has been concerned in the study of imatinib drug resistance. This review will focuses on the latest research progress on the mechanism of C-Myc in chronic myeloid leukemia in recent years.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app